At what stage of the adoption of a neuromorphic SNN technology do non-disclosure agreements have a cost benefit ratio less than one? What are some critical milestones that need to be met before the use of new technology becomes a positive selling point for adopters?
chatgpt: 'Non-disclosure agreements (NDAs) are typically used in the early stages of technology development to protect intellectual property, trade secrets, and other confidential information. As the technology moves closer to commercialization, the cost-benefit ratio of NDAs may decrease, as companies need to share information with potential partners and customers to generate interest and secure funding.
In the case of neuromorphic SNN technology, critical milestones that need to be met before the use of the new technology becomes a positive selling point for adopters include:Once these critical milestones are met, the benefits of disclosing information about the technology may outweigh the costs of using NDAs, as potential partners and customers may be more willing to invest in and adopt the technology."
- . Demonstrated performance: The technology needs to be shown to work reliably and effectively in a range of applications.
- . Scalability: The technology needs to be scalable to meet the needs of large-scale applications.
- . User-friendly interface: The technology needs to have a user-friendly interface that allows non-experts to easily use and integrate the technology into their systems.
- . Cost-effectiveness: The technology needs to be cost-effective, both in terms of the hardware and software required to implement it and in terms of the time and effort required to learn and use the technology.
- . Regulatory compliance: The technology needs to comply with relevant regulations, including those related to safety, privacy, and data protection.
Not a bad response I thought!
- Forums
- ASX - By Stock
- BRN
- 2023 BrainChip Discussion
2023 BrainChip Discussion, page-442
Featured News
Add BRN (ASX) to my watchlist
(20min delay)
|
|||||
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $581.8M |
Open | High | Low | Value | Volume |
29.0¢ | 30.0¢ | 27.0¢ | $7.028M | 24.51M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 1879470 | 29.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 752200 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 1814488 | 0.290 |
6 | 761316 | 0.285 |
17 | 765645 | 0.280 |
31 | 1067302 | 0.275 |
45 | 1085792 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.295 | 752200 | 5 |
0.300 | 537790 | 11 |
0.305 | 1516690 | 16 |
0.310 | 1093627 | 33 |
0.315 | 645597 | 13 |
Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
Featured News
BRN (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, MD & CEO
Charles Armstrong
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online